SMMT · Summit Therapeutics Inc.
$16.82
+0.13 (+0.76%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jul 23, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jul 23, 2026
Market Cap
$12.45B
Shares
797.75M
Volume · Oct 2
5.2M
Avg daily vol (3M)
5.64M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.69
Open$16.82
Day$16.59–17.50
52W close$12.43–26.38
Avg vol 30d7.2M
Short int41.1M · 5.1% float · 6.6d
Short vol49%
Last earningsJul 23, 2026
DataJan 2020–Oct 2026
Filing10-Q · Jul 23
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 6 wks
filed Jul 23, 2026
call held Jul 23, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$856.09M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-3.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$690.68M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.8%
Year over year · more shares
Price change (1Y)
-18.5%
Trailing year
Short interest
5.1%
Latest settlement · 6.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
+11%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
31%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+14%
trailing
6-month return
−15%
trailing
YTD return
−5%
this year
Relative strength
−28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $16 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +57 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.15% of float · ▼ -0.6% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
248 holders — near 3-yr high, broad support
Squeeze score
81
high risk · 0–100
Fundamentals
EPS growth
−365%
Y/Y
Free cash flow
$-323.6M
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
31%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $15 › 200d $16 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +57 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.15% of float · ▼ -0.6% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
248 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $12
Now $17 · 31%
Range high $26
vs 200-day avg +2%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SMMT
this stock
Summit Therapeutics Inc.
|
$12.45B | -4.6% | — | — | 5.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +540.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SMMT | +1.9% | +14.3% | -15.2% | -1.3% | -4.6% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +2.3% | +14.5% | -27.6% | -1.5% | -16.6% |